P/B
1,8
Biogen
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
$33.3B
Market Cap • 10/9/2026
1997
(29 years)
Founded
1991
(35 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
S&P500 Participant
Index Composite • 2026
Valuation
P/S
3,3
P/EBITDA
15,8
P/OCF
11,6
P/FCF
12,4
P/E
39,9
BVPS
127,6
EPS
5,6
Market Cap
Market Cap
33,3B
EV
40,4B
EV/Revenue
4
EV/EBITDA
19,1
EV/EBIT
31,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
21B
Profitability
Gross Margin
74%
EBITDA Margin
21,1%
EBIT Margin
12,7%
Net Margin
8,3%
D&A/EBITDA
27,3%
R&D/Revenue
24,3%
Capex/Revenue
1,8%
Capex/D&A
21,6%
Capex/OCF
6,3%
SBC/OCF
10,3%
% PPE
0,8%
% Goodwill
21,8%
ROE
4,6%
ROIC
4,2%
Growth
CAGR Revenue 5Y
-3%
CAGR Op. Income 5Y
-9,8%
CAGR Net Income 5Y
-19,6%
CAGR EPS 5Y
-14,6%
CAGR OCF 5Y
0,5%
Leverage
N.D./EBITDA
3,3
Debt/Equity
0%
Current Ratio
1,9
Quick Ratio
0,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!